Artiva shuts autoimmune cell therapy trial after two patient deaths

STAT reports that Artiva is shutting down its autoimmune cell therapy trial after two patients died. The news comes as drugmakers have shown interest in using cancer therapy strategies for autoimmune conditions, but these recent deaths have raised new concerns about safety and risk.

For senior executives in biotech and pharma, this development signals increased scrutiny on adapting cancer treatments for other diseases. Companies may need to reassess trial protocols and risk management processes. The outcome may affect investor confidence and regulatory expectations in the sector.